Skip to main content

Advertisement

SpringerLink
Log in

Patient-Centric Strategies for Drug Re-innovation

  • Review Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Drug repurposing, often achieved via the FDA’s 505(b) (2) pathway, is an increasingly popular approach in today’s pharmaceutical environment. Repurposing or “re-innovation” comprises a multitude of techniques, which have resulted in wide-ranging commercial success. This article explores the diverse strategies that have been taken to repurpose drugs, and distinguishes a unifying theme among the most commercially successful examples—the ability to address significant unmet needs. The examples listed in this paper relate to small molecules drugs and certainly not exhaustive, however provide some of the key strategies that have been successful using “re-innovation” pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. Accutane is a registered trademark of Hoffmann-La Roche Limited; Absorica is a registered trademark of Ranbaxy Laboratories Inc.; Lidose is a trademark of Galephar Pharmaceutical Research, Inc.; Jentadueto XR is a registered trademark of Boehringer Ingelheim; Zubsolv is a registered trademark of Orexo US, Inc.; Suboxone is a registered trademark of Indivior (UK) Limited; Ulceris is a registered trademark of Valeant Pharmaceuticals International, Inc.; MMX is a registered trademark of Intel Corp.; Abraxane is a registered trademark of Abraxis BioScience, LLC; Cremophor is a registered trademark of BASF SE; Vimovo is a registered trademark of AstraZeneca UK Limited; Xtampza ER and DETERx are registered trademarks of Collegium Pharmaceutical, Inc.; Bendeka and Treanda are registered trademarks of Cephalon, Inc.; Exparel and DepoFoam are registered trademarks of Pacira Pharmaceuticals, Inc.; Voltaren Gel is a registered trademark of Novartis AG; Doryx MPC is a registered trademark of Mayne Pharmaceuticals; Monodox is the registered trademark of Aqua Pharmaceuticals, LLC; Onzetra is a registered trademark of Avanir Pharmaceuticals, Inc.; Imitrex is a registered trademark of the GlaxoSmithKline group of companies; and Vyvanse is a registered trademark of Shire LLC

References

  1. Suchak R, Murray LJ. Generic portfolio management: a paradigm for minimizing risk and maximizing value. Journal of Generic Medicines. 2016;13:63 http://journals.sagepub.com/doi/abs/10.1177/1741134316677850.

    Google Scholar 

  2. Financial Times https://www.ft.com/content/6645b174-2371-11e8-ae48-60d3531b7d11

  3. US FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm591184.htm

  4. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1):13–9. 

    Article  Google Scholar 

  5. Center for Drug Evaluation and Research (CDER). Guidance for industry: applications covered by section 505(b)(2). 1999. http://www.fda.gov/downloads/Drugs/Guidances/ucm079345.pdf.

  6. Sario N. Prescription Drug Market: The World Is Turning to Generics; Part 5 of 17: Specialty Generics: Why are they getting more attention? 2015. http://marketrealist.com/2015/03/specialty-generics-getting-attention/

  7. Barei F, Ross M. The refinement of the super generic concept: semantic challenge for product re-innovation? Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(1):25–32.

  8. Regulatory Affairs Professional Society. 2015. http://www.raps.org/Regulatory-Focus/News/2015/04/08/21933/An-Increasing-Number-of-Companies-Are-Using-a-Once-Obscure-FDA-Drug-Approval-Pathway/.

  9. Camargo. https://camargopharma.com/2018/01/2017-505b2-nda-approvals-increase-dramatically-and-review-times-decrease/

  10. New Drugs are FDA https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm

  11. ABSORICA®. http://absorica.com/ Accessed October 25, 2017.

  12. ABSORICA® Patient Brochure. http://absorica.com/patient-brochure.pdf’. Accessed October 25, 2017.

Download references

Acknowledgments

The views and opinions expressed in this article are those of the authors and do not necessarily reflect those of Novartis Pharmaceuticals Corporation or Sandoz Inc.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Sandoz Inc., 100 College Rd West, Princeton, NJ, 08540, USA

    Kinjal Suchak & Lisa J. Murray

Authors
  1. Kinjal Suchak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa J. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kinjal Suchak.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Appendix

Appendix

Table 2 Summary of the key re-innovation examples discussed in article
Full size table
Table 3 Glossary of acronyms in Table 1
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suchak, K., Murray, L.J. Patient-Centric Strategies for Drug Re-innovation. J Pharm Innov 14, 187–193 (2019). https://doi.org/10.1007/s12247-018-9351-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-018-9351-z

Keywords

Search

Navigation